Home/Celularity/Geoffrey Shiu Fei Ling
GS

Geoffrey Shiu Fei Ling

Director

Celularity

Celularity Pipeline

DrugIndicationPhase
Placental-derived biomaterial productsWound care / Tissue regenerationApproved/Commercial
MLASC-based therapiesDegenerative DiseasesPhase 1/2
NK Cell therapiesOncologyPhase 1/2
T Cell therapiesImmunology/OncologyPhase 1/2